Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420602
Status:
COMPLETED
Last Update Posted:
2018-05-09
First Post:
2007-01-10
Brief Title:
DHA Supplementation in Patients With STGD3
Sponsor:
University of Utah
Organization:
University of Utah
Study Overview
Official Title:
Clinical Interventions Against Stargardt Macular Dystrophy DHA Supplementation in Patients With STGD3
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We have found that biomarkers of long-term elevated dietary intake of omega-3 fatty acids such as DHA and EPA are inversely associated with severity of disease phenotype in STGD3 patients Therefore the purpose of this study is to follow STGD3 patients as they supplement their diets with DHAEPA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None